Obvious Ventures, Pear VC, GenHealth presents: Generative AI in Healthcare
Get ready to dive into the future of healthcare! We're thrilled to have you join us right in the heart of San Francisco.
Come ready to mingle, learn, and meet healthcare folks in AI! We can't wait to see you there!
We have limited spots so if you're approved the location will be sent out. We reached max capacity - we're only hosting a small gathering this time so unfortunately cannot accept everyone.
About Obvious Ventures: Obvious is a venture capital firm investing in early-stage, purpose-driven entrepreneurs reimagining trillion-dollar industries. Obvious has over $1 billion AUM. Select investments include Virta, Devoted Health, GenHealth and Galileo in healthcare; Zymergen, Recursion Pharmaceuticals, and LabGenius in computational biology; Proterra, Lilium, and Amply in electrified transportation; Hedvig, One Finance, Corvus, and Openly in fintech; and Incredible Health and Gusto, platforms helping people thrive at work.
About Pear VC: Pear is a pre-seed and seed stage VC firm that partners with entrepreneurs from their earliest days to build category defining companies. We've invested in top-tier companies including Doordash, Viz.AI, Valar Labs, Recora, ixLayer, Gusto, Branch, Guardant Health, Bioage, Vanta, SentiBio and so many more. We're company builders, having founded 10 companies: we help companies find product-market fit, recruit their first engineering hire, and overcome other critical business challenges. Keep up with Pear at Pear Healthcare Playbook Podcast!
About Genhealth.ai: GenHealth is a startup building the next generation of AI-powered healthcare solutions using generative AI. Our approach trains a transformer model on millions of patients’ encoded claims and clinical data to predict their futures. GenHealth’s model can be used as a digital twin or co-pilot supporting a broad set of use cases. Among them, health insurance plans can use GenHealth to better understand quality and risk, providers can find the next best action, pharma can simulate clinical trials, and life insurance can have more personalized actuarial analysis.